ArticleCombinatorial chemistry & high throughput screening2025
Fuzi-Baijiangcao Herb Pair Alleviates DSS-induced Ulcerative Colitis in Mice via Inhibiting the p38 MAPK/NF-κB/HIF-1α Signaling Pathway.
Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bee venom acupuncture therapy ameliorates ulcerative colitis by reducing inflammatory response, oxidative stress, and suppressing the NF-κB/HIF-1α pathway.Open life sciences · 2026Article
- Unveiling Yiyi Fuzi Baijiang powder: Microecological and network pharmacology approach to ulcerative colitis treatment.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis is an inflammatory intestinal tract disease that is complex and, difficult to heal, and prone to recurrence. The Fuzi-Baijiangcao (FB) herb pair is a commonly used drug combination for the clinical treatment of UC in China. However, its underlying mechanisms have not been elucidated. In this study, we explored the active ingredients of the FB herb pair and its potential mechanisms in the treatment of UC.
methodsFirstly, the active ingredients and potential targets of Aconitum carmichaelii Debeaux (Fuzi) and Patrinia villosa (Thunb.) Juss (Baijiangcao) were obtained through network pharmacology. We identified differentially expressed genes (DEGs) in UC by bioinformatics analysis. Then, the common targets of the FB herb pair and UC were obtained, and the protein-protein interaction (PPI) network was constructed. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using R language. The potential mechanism of the herb pair was validated through DSS induced UC mouse model.
resultsThirty-four active ingredients corresponding to 546 potential targets were screened in the FB herb pair. Bioinformatics analysis revealed 2125 DEGs in UC. The GO and KEGG enrichment analyses showed that the FB herb pair was able to exert therapeutic effects by modulating multiple inflammatory pathways, including MAPK, HIF-1, and TNF. The results of animal experiments demonstrated that the FB herb pair could significantly downregulate the gene and protein expression of key molecules in the p38 MAPK/NF-κB/HIF-1α signaling pathway, thereby reducing the expression of pro-inflammatory factors and cell adhesion molecules, significantly improving the symptoms and intestinal pathology, and repairing the damage of the intestinal mucosa in the UC mice.
conclusionsFB herb pair has Apparent therapeutic effects on UC, and its mechanisms may be related to the regulation of the p38 MAPK/NF-κB/HIF-1α signaling pathway to reduce the expression of inflammatory factors and repair intestinal mucosal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.